RIDGEWATER, N.J., September 11, 2025 – Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for sodium oxybate oral solution 500 mg/mL, a generic referencing Jazz Pharmaceuticals’ Xyrem®. This approval enables Amneal to commercialize its own version of this critical narcolepsy treatment, further expanding its Affordable Medicines portfolio and broadening patient access in a market long dominated by a single manufacturer.
Science Significance
Sodium oxybate is a central nervous system depressant that reduces excessive daytime sleepiness (EDS) and cataplexy—sudden muscle weakness triggered by emotions—in patients with narcolepsy. The product consolidates nighttime sleep and lowers the frequency of cataplexy episodes, making it the standard of care for a rare neurological disorder affecting approximately 150,000 individuals in the United States. Amneal’s formulation delivers a scientifically equivalent therapeutic option to the reference drug, providing clinicians and patients with the same clinical benefits supported by well-established evidence.
Regulatory Significance
The FDA approval reflects the agency’s ongoing efforts to promote generic competition in complex and specialty drug categories. By clearing Amneal’s ANDA, the FDA supports market diversification in a product category previously controlled by a single brand. This decision aligns with federal initiatives to encourage generic entry for high-cost therapies and underscores the importance of maintaining rigorous quality and bioequivalence standards while ensuring patient safety.
Business Significance
Advertisement
The approval reinforces Amneal’s strategic focus on complex generics and specialty pharmaceuticals, key growth drivers for the company’s Affordable Medicines segment. “This approval expands Amneal’s Affordable Medicines portfolio into a critical therapy area for patients living with narcolepsy,” said Tony Rosa, Senior Vice President of Retail Affordable Medicines. The launch of sodium oxybate strengthens Amneal’s U.S. generics business by introducing a cost-effective alternative in a high-value, underserved market where payer pressure for lower-cost options remains intense.
Patients’ Significance
For narcolepsy patients and caregivers, the availability of a more affordable sodium oxybate product represents a meaningful breakthrough in access and affordability. Treatment for narcolepsy has historically been limited to one manufacturer, leaving patients vulnerable to high out-of-pocket costs and supply constraints. Amneal’s entry offers a reliable, lower-cost therapy while maintaining the safety profile of the reference product. Common side effects include nausea, dizziness, vomiting, and somnolence in adults, with pediatric patients also reporting headache, decreased appetite, and sleepwalking.
Policy Significance
This approval aligns with federal and state health policy objectives aimed at reducing prescription drug costs through generic competition. It also supports the Biden administrations and FDA’s broader goals to expand the availability of generics for rare diseases and complex neurological conditions. By diversifying supply in a high-cost market, Amneal’s sodium oxybate product could help payers, including Medicare and Medicaid, manage spending on specialty medications and improve healthcare system sustainability.
Transaction Highlights
Amneal Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for sodium oxybate oral solution 500 mg/mL, a generic equivalent of Jazz Pharmaceuticals’ Xyrem®. This milestone allows Amneal to commercialize its own formulation after previously distributing an authorized generic in limited quantities, expanding its Affordable Medicines portfolio into the rare neurological disorder space. The product is indicated for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy, a condition that affects roughly 150,000 people in the United States. By launching this high-value therapy, Amneal will provide a more affordable and competitive option in a market historically controlled by a single manufacturer, helping patients, providers, and payers gain broader access to an essential treatment while reinforcing the company’s growth strategy in complex generics and specialty therapies.
Source: Amneal Pharmaceuticals, Inc. Press Release
